Information  X 
Enter a valid email address

Amryt Pharma PLC Ord 6P Ord Ne (AMYT)

Date Time Source Announcement
23 Nov 2021 12:00 pm
GNW
Amryt Provides Update on Regulatory Review Process for Oleogel-S10
22 Nov 2021 7:00 am
GNW
Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
03 Nov 2021 11:00 am
GNW
Amryt Reports Strong Q3 2021 Results
01 Nov 2021 1:00 pm
GNW
Total Voting Rights
  7:00 am
RNS
Amryt Supports Acromegaly Awareness Day
22 Oct 2021 7:00 am
RNS
Amryt Supports Global EB Awareness Week 2021
20 Oct 2021 12:00 pm
GNW
Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19 Oct 2021 12:00 pm
GNW
Amryt Announces New Patents for Oleogel-S10 and Mycapssa®
01 Oct 2021 7:00 am
GNW
Total Voting Rights
23 Sep 2021 12:00 pm
RNS
Amryt Supports Global FH Awareness Day
13 Sep 2021 12:00 pm
GNW
Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
01 Sep 2021 7:00 am
GNW
Total Voting Rights
19 Aug 2021 7:00 am
GNW
Amryt Issues Ordinary Shares and Total Voting Rights
13 Aug 2021 1:23 pm
RNS
Holding(s) in Company - Replacement
11 Aug 2021 11:30 am
RNS
Holdings in Company
  10:36 am
RNS
Holding(s) in Company
10 Aug 2021 2:20 pm
GNW
Director/PDMR Shareholding
  9:53 am
RNS
Holding(s) in Company
09 Aug 2021 12:00 pm
GNW
Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
06 Aug 2021 12:00 pm
GNW
Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
05 Aug 2021 3:50 pm
GNW
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28 Jul 2021 3:00 pm
GNW
Result of General Meetings
12 Jul 2021 12:00 pm
GNW
Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28 Jun 2021 12:00 pm
GNW
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15 Jun 2021 11:45 am
GNW
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
07 Jun 2021 12:00 pm
GNW
FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
03 Jun 2021 7:00 am
GNW
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
02 Jun 2021 1:30 pm
GNW
Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
05 May 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  12:05 pm
GNW
Amryt Reports Record Q1 2021 Financial and Operating Results
  12:00 pm
GNW
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15 Apr 2021 12:00 pm
GNW
Amryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
06 Apr 2021 7:00 am
GNW
Amryt Announces the Appointment of Sheila Frame as President Americas
31 Mar 2021 11:00 am
RNS
Amryt Supports World Lipodystrophy Day
  7:00 am
GNW
Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30 Mar 2021 7:00 am
GNW
Amryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29 Mar 2021 7:00 am
GNW
Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23 Mar 2021 7:00 am
GNW
Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22 Mar 2021 7:00 am
GNW
Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15 Mar 2021 10:00 am
GNW
Director/PDMR Shareholding
12 Mar 2021 7:00 am
GNW
Exercise of Options and Total Voting Rights
11 Mar 2021 11:30 am
GNW
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
08 Mar 2021 6:00 pm
GNW
Director/PDMR Shareholding
  7:00 am
GNW
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
04 Mar 2021 12:00 pm
RNS
Amryt Announces Record FY 2020 Results
25 Feb 2021 7:00 am
RNS
Amryt Supports Global Rare Disease Day 2021
24 Feb 2021 7:00 am
GNW
Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10 Feb 2021 7:00 am
RNS
Amryt to Present at SVB Leerink Conference
04 Feb 2021 7:00 am
GNW
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20 Jan 2021 7:00 am
GNW
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
06 Jan 2021 7:00 am
RNS
Amryt to present at H.C Wainwright Conference
23 Dec 2020 7:00 am
GNW
Amryt Granted Orphan Drug Designation by the FDA for AP103
17 Dec 2020 7:00 am
GNW
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11 Dec 2020 10:00 am
GNW
Holding(s) in Company
09 Dec 2020 2:45 pm
GNW
Holding(s) in Company
  7:00 am
GNW
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
08 Dec 2020 7:00 am
GNW
Amryt Announces $40m Private Placement with Leading Biotech Investors
05 Nov 2020 12:00 pm
GNW
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29 Oct 2020 7:00 am
GNW
AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA

a d v e r t i s e m e n t